Drug Profile
Bebtelovimab - Eli Lilly and Company
Alternative Names: LY-3853113; LY-CoV 1404 mAb; LY-CoV1404; LY-CoV1404 monoclonal antibodyLatest Information Update: 20 Feb 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Abcellera; Eli Lilly and Company
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration COVID 2019 infections
Most Recent Events
- 16 Feb 2023 US FDA unauthorises the use of Bebtelovimab for COVID-2019 infections (In adolescents, In adults, In children, Mild to moderate-stage disease) in USA
- 30 Nov 2022 US FDA unauthorises the use of bebtelovimab under emergency use authorization for COVID-2019 infections (Early-stage disease, In adolescents, In adults, In children, Mid-stage disease, Monotherapy) in USA
- 04 Aug 2022 Eli Lilly intends to make Bebtelovimab commercially available for purchase by U.S. states/territories, hospitals, and a broad set of other providers through a sole distributor.